Obesity “wonder drug” Wegovy is expected to be on sale in Ireland in the next 10 days but, even now, the woman charged with overseeing new product launches of the drug’s developer ...

In January, they were overtaken by Novartis’ Pluvicto and Johnson & Johnson’s Tremfya; last month, it was Novo Nordisk’s Wegovy and J&J’s immunology med that leapfrogged over the previous ...

HYDERABAD, April 7 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with ...

Wegovy is prescribed for weight management and to lower the risk of cardiovascular problems. During the first week of treatment, weight loss is possible, but it may take time to see the full ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

Ozempic (semaglutide) and Wegovy (semaglutide) are brand-name injections. Ozempic is approved for type 2 diabetes, but doctors may sometimes prescribe it off-label for weight loss and management.

Wegovy is a semaglutide prescription injection developed by Danish healthcare company Novo Nordisk Pharmaceuticals. Semaglutide acts to regulate someone’s appetite to increase their feeling of ...

STORY: Weight-loss drug Wegovy has driven Novo Holdings to fresh highs. The company said Wednesday (April 2) it nearly doubled annual income and investment returns to a record $8.66 billion last year.

Investing.com -- Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE:NOVOb) (NYSE:NVO) ahead of its Q1 2025 report, citing weaker-than-expected prescription volumes for key ...

Semaglutide is available as Wegovy and Ozempic injections, and also as Rybelsus tablets. The study's findings indicate a potential link between these medications and a lower risk of dementia.

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum ...